TrialNature medicine2023

CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.

Jae H Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.